Analysis of immune-related adverse events after treatment with trelizumab in patients with non-small cell lung cancer
Objective To investigate the frequency and characteristics of immune-related adverse events(irAEs)following treatment with trelizumab in patients with non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on clinical data of 114 NSCLC patients receiving treatment with trelizumab in Xuzhou Central Hospital from June 2022 to December 2023.The patients were divided into a monotherapy group of 42 cases(trelizumab)and a combination group of 72 cases(trelizumab combined with vasodilators or targeted therapy drugs)based on their medication regimen.irAEs were analyzed in both groups.Results Sixteen of the 42 patients(38.10%)in the monotherapy group developed a total of 53 irAEs presented by frequent occurrence of rash,infusion reactions and immune-related diarrhea.Forty-three of the 72 patients(59.72%)in the combination group developed a total of 192 irAEs presented by frequent appearance of rash,infusion reactions,immune-related diarrhea and loss of appetite.The incidence of irAEs such as immunological liver injury,immune-related arthritis,pulmonary infections,rash,pruritus,infusion reactions and loss of appetite was significantly lower in the monotherapy group than in the combination group(t=4.11,4.038,6.050,4.283,5.348,4.361 and 4.343,all P<0.05).Conclusion The frequency of irAEs in patients with NSCLC receiving trelizumab monotherapy is less than that in those undergoing combination therapy.These irAEs are generally controllable.However,the patients may experience serious injuries or even life-threatening injuries without appropriate interventions as well as therapeutic measures.
NETL
NSTL
万方数据
